Axsome Therapeutics Inc will present new data on Sunosi (solriamfetol) at SLEEP 2023.

The presentations include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), demonstrating sustained improvement with Sunosi on measures of cognition across eight-hours with once-daily dosing. 

Additional new data and analyses include real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.

“Cognitive impairment is a substantial burden to many patients with EDS and OSA. The results of the SHARP study are particularly exciting because they demonstrate a robust improvement in cognitive function that was sustained throughout the day,” says Hans Van Dongen, PhD, professor at Washington State University and first author of the SHARP study abstract. “Not only was there an objective change in cognitive performance, but patients also reported a measurable improvement in their symptoms, suggesting solriamfetol can be an effective option for the treatment of patients with EDS due to OSA.”

Details for the upcoming SLEEP Meeting presentations are as follows:

Title: Solriamfetol Demonstrates Durable Cognitive Improvement in Adults with Obstructive Sleep Apnea and Excessive Daytime Sleepiness

Poster Session: P-29

Lead Author: Hans Van Dongen, PhD, Professor at Washington State University

Date/Time: June 6, 2023, from 5 – 6 pm ET

Poster Board Number: 168

Title: SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in German

Poster Session: P-29

Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany

Date/Time: June 6, 2023, from 12 – 1:15 pm ET

Poster Board Number: 169

Title: Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

Poster Session: P-29

Lead Author: Russell Rosenberg, PhD, NeuroTrials Research, Atlanta, GA

Date/Time: June 6, 2023, from 5 – 6 pm ET

Poster Board Number: 170

Title: Healthcare Resource Utilization Burden 1 Year Post Continuous Positive Airway Pressure Initiation Among Adults with Excessive Daytime Sleepiness in Obstructive Sleep Apnea in the United Kingdom

Poster Session: P-12

Lead Author: Gregory Parks, PhD, Axsome Therapeutics

Date/Time: June 6, 2023, from 12 – 1:15 p.m. ET

Poster Board Number: 229

Sunosi received US Food and Drug Administration approval on March 20, 2019, to improve wakefulness in adult patients with EDS associated with narcolepsy or OSA.